CSNK1D: A Potential Drug Target and Biomarker for ALS-Like Neurodegenerative Diseases

Target Name: CSNK1D

NCBI ID: G1453

CSNK1D

CSNK1D: A Potential Drug Target and Biomarker for ALS-Like Neurodegenerative Diseases

Neurodegenerative diseases, such as Alzheimer's disease, Parkinson's disease, and Huntington's disease, are progressive neurological disorders that affect millions of people worldwide, leading to significant morbidity and mortality. These conditions are characterized by the progressive loss of brain cells, leading to the development of neurofibrillary tangles and neurogenic markers. The search for new treatments and biomarkers for these diseases has become a major focus in the pharmaceutical industry, with a significant impact on disease management and improved quality of life.

CSNK1D: A Potential Drug Target and Biomarker

The protein kinase CSNK1D (EC 506855) is a potential drug target and biomarker for ALS-like neurodegenerative diseases. It is a non-muscle protein that is expressed in various tissues, including brain, heart, and skeletal muscles. The CSNK1D gene has 118 amino acid residues and is localized to the endoplasmic reticulum (ER) and nuclear envelope (NE).

CSNK1D functions as a protein kinase, which plays a crucial role in the regulation of a variety of cellular processes, including cell growth, differentiation, and survival. The CSNK1D kinase has been shown to be involved in the regulation of several cellular processes, including cell adhesion, migration, and survival.

In neurodegenerative diseases, the misregulation of CSNK1D has been implicated in the development and progression of these conditions. Several studies have shown that the CSNK1D gene is often mutated or downregulated in neurodegenerative diseases, such as ALS (Amyotrophic Lateral Sclerosis), a progressive motor neuron disease that is characterized by the progressive loss of motor neurons.

CSNK1D as a Potential Drug Target

The CSNK1D gene has been identified as a potential drug target for ALS-like neurodegenerative diseases due to its involvement in several cellular processes that are affected in these conditions. One of the main targets of CSNK1D is the regulation of microtubule dynamics, which is critical for the proper functioning of motor neurons.

Studies have shown that the CSNK1D gene is involved in the regulation of microtubule stability and dynamics, which is crucial for the proper functioning of motor neurons. Mutilation of the CSNK1D gene has been shown to result in the misfunctioning of microtubules and the development of neurodegenerative diseases.

In addition to its role in microtubule dynamics, CSNK1D has also been shown to be involved in the regulation of several other cellular processes that are affected in neurodegenerative diseases, such as the regulation of cell adhesion, migration, and survival.

CSNK1D as a Potential Biomarker

The CSNK1D gene has also been shown to be a potential biomarker for ALS-like neurodegenerative diseases. Several studies have shown that the expression of the CSNK1D gene is affected in neurodegenerative diseases, including ALS, and that the levels of this gene have been shown to be reduced in these conditions.

In addition to its potential as a drug target, CSNK1D has also been shown to be a potential biomarker for ALS-like neurodegenerative diseases. Several studies have shown that the levels of CSNK1D have been reduced in the brains of patients with ALS, and that the expression of this gene has been shown to be affected in ALS patients.

Conclusion

In conclusion, CSNK1D is a potential drug target and biomarker for ALS-like neurodegenerative diseases. Its involvement in the regulation of microtubule dynamics and its expression in neurodegenerative diseases make it an attractive target for drug development. Further research is needed to fully understand the role of CSNK1D in

Protein Name: Casein Kinase 1 Delta

Functions: Essential serine/threonine-protein kinase that regulates diverse cellular growth and survival processes including Wnt signaling, DNA repair and circadian rhythms. It can phosphorylate a large number of proteins. Casein kinases are operationally defined by their preferential utilization of acidic proteins such as caseins as substrates. Phosphorylates connexin-43/GJA1, MAP1A, SNAPIN, MAPT/TAU, TOP2A, DCK, HIF1A, EIF6, p53/TP53, DVL2, DVL3, ESR1, AIB1/NCOA3, DNMT1, PKD2, YAP1, PER1 and PER2. Central component of the circadian clock. In balance with PP1, determines the circadian period length through the regulation of the speed and rhythmicity of PER1 and PER2 phosphorylation. Controls PER1 and PER2 nuclear transport and degradation. YAP1 phosphorylation promotes its SCF(beta-TRCP) E3 ubiquitin ligase-mediated ubiquitination and subsequent degradation. DNMT1 phosphorylation reduces its DNA-binding activity. Phosphorylation of ESR1 and AIB1/NCOA3 stimulates their activity and coactivation. Phosphorylation of DVL2 and DVL3 regulates WNT3A signaling pathway that controls neurite outgrowth. Phosphorylates NEDD9/HEF1 (By similarity). EIF6 phosphorylation promotes its nuclear export. Triggers down-regulation of dopamine receptors in the forebrain. Activates DCK in vitro by phosphorylation. TOP2A phosphorylation favors DNA cleavable complex formation. May regulate the formation of the mitotic spindle apparatus in extravillous trophoblast. Modulates connexin-43/GJA1 gap junction assembly by phosphorylation. Probably involved in lymphocyte physiology. Regulates fast synaptic transmission mediated by glutamate

The "CSNK1D Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about CSNK1D comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets